
Clene Inc. (NASDAQ: CLNN) To Conduct Neurofilament Biomarker Analysis For CNM-Au8(R) In ALS In Early Q4 2025
(MENAFN- Investor Brand Network) The FDA offered supportive feedback on Clene's proposed statistical analysis plan during a recent Type C meeting. The neurofilament biomarker analysis results could support an accelerated approval submission for CNM-Au8 …